Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells

5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to...

Full description

Saved in:
Bibliographic Details
Published inArchives of pharmacal research Vol. 38; no. 2; pp. 239 - 248
Main Authors Kim, Sun-Ah, Kim, Injung, Yoon, Sungjoo Kim, Lee, Eun Kyung, Kuh, Hyo-Jeong
Format Journal Article
LanguageEnglish
Published Heidelberg Pharmaceutical Society of Korea 01.02.2015
대한약학회
Subjects
Online AccessGet full text
ISSN0253-6269
1976-3786
1976-3786
DOI10.1007/s12272-014-0528-9

Cover

Abstract 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.
AbstractList 5-FU is an anticancer drug that is widely used totreat cancers, including colorectal cancer (CRC); however,chemoresistance to 5-FU remains an important problem tobe resolved. The role of microRNAs (miRs) in chemosensitivityhas recently been studied in the development oftherapeutic strategies to overcome drug resistance. Here, wefocused on miR-96, which has been reported to demonstratechemosensitivity. We investigated whether 5-FU sensitivitymay be modulated by miR-96 in monolayer cells and whetherthis relationship also applies for drug resistance in 3Dtumor spheroids (TSs). When the level of miR-96 increased,the expression of the anti-apoptotic regulator XIAP and p53stability regulator UBE2N decreased, resulting in increasedapoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpressionof XIAP and UBE2N, yet only minimal change wasinduced in apoptosis. Nonetheless, luciferase assay failed toshow direct interactions between miR-96 and these genes. InTSs, 5-FU resistance corresponded to a significantly lowerlevel of miR-96, however only XIAP, not UBE2N, was upregulateddemonstrating partial agreement with the 2Dcondition regarding target expression. Overall, these resultssuggest that miR-96 may modulate 5-FU sensitivity in CRCcells by promoting apoptosis; however, differential expressionof target genes in TSs warrants further studies on the5-FU resistance mechanism under 3D conditions. KCI Citation Count: 35
5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.
5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.
5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important problem to be resolved. The role of microRNAs (miRs) in chemosensitivity has recently been studied in the development of therapeutic strategies to overcome drug resistance. Here, we focused on miR-96, which has been reported to demonstrate chemosensitivity. We investigated whether 5-FU sensitivity may be modulated by miR-96 in monolayer cells and whether this relationship also applies for drug resistance in 3D tumor spheroids (TSs). When the level of miR-96 increased, the expression of the anti-apoptotic regulator XIAP and p53 stability regulator UBE2N decreased, resulting in increased apoptosis and growth inhibition following 5-FU exposure. Transfection of miR-96 inhibitors resulted in an overexpression of XIAP and UBE2N, yet only minimal change was induced in apoptosis. Nonetheless, luciferase assay failed to show direct interactions between miR-96 and these genes. In TSs, 5-FU resistance corresponded to a significantly lower level of miR-96, however only XIAP, not UBE2N, was up-regulated demonstrating partial agreement with the 2D condition regarding target expression. Overall, these results suggest that miR-96 may modulate 5-FU sensitivity in CRC cells by promoting apoptosis; however, differential expression of target genes in TSs warrants further studies on the 5-FU resistance mechanism under 3D conditions.
Author Kim, Sun-Ah
Kim, Injung
Lee, Eun Kyung
Yoon, Sungjoo Kim
Kuh, Hyo-Jeong
Author_xml – sequence: 1
  givenname: Sun-Ah
  surname: Kim
  fullname: Kim, Sun-Ah
  organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea
– sequence: 2
  givenname: Injung
  surname: Kim
  fullname: Kim, Injung
  organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea
– sequence: 3
  givenname: Sungjoo Kim
  surname: Yoon
  fullname: Yoon, Sungjoo Kim
  organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea
– sequence: 4
  givenname: Eun Kyung
  surname: Lee
  fullname: Lee, Eun Kyung
  organization: Department of Biochemistry, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea
– sequence: 5
  givenname: Hyo-Jeong
  surname: Kuh
  fullname: Kuh, Hyo-Jeong
  email: hkuh@catholic.ac.kr
  organization: Department of Medical Lifesciences, College of Medicine, The Catholic University of Korea, Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25502560$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001962657$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqFkT1v1TAYhS1URG8LP4AFeYTB4I-8jj1eVXxcqQKpKrPlOE5xm9jFTpDuv8dp2oWhTO_g5xxZ5zlDJzFFj9BbRj8ySttPhXHeckJZQyhwRfQLtGO6lUS0Sp6gHeUgiORSn6KzUm4pFRIAXqFTDlDfJN2h_hD7kL2b8ZT6ZbRzSBGnARcfS5jDnzAf8ZwwkGFcUk5Lti6MuDviKbicrr7viZY4RPxrmWzELo1pLbMjdjY6n7Hz41heo5eDHYt_83jP0c8vn68vvpHLH18PF_tL4pqmmYmSqus91cp7atXAdMddC06DHqTWEjylnQXZN50GJT1TqpOib3vGfdM3Qopz9GHrjXkwdy6YZMPDvUnmLpv91fXBMCZkC1DZ9xt7n9PvxZfZTKGsv7XRp6UY1goBVOhG_R-VwBsQFHRF3z2iSzf53tznMNl8NE-DV6DdgLpeKdkPxoX5YfU52zAaRs2q1mxqTVVrVrVmrWb_JJ_Kn8vwLVMqG298NrdVYawOngn9BQTPs8I
CitedBy_id crossref_primary_10_2174_1570180818666210930161618
crossref_primary_10_20517_cdr_2024_167
crossref_primary_10_3390_cancers10110440
crossref_primary_10_1016_j_mam_2019_04_002
crossref_primary_10_1016_j_cca_2020_05_012
crossref_primary_10_1016_j_prp_2023_154701
crossref_primary_10_1186_s13046_017_0654_6
crossref_primary_10_1016_j_adcanc_2022_100082
crossref_primary_10_3892_or_2016_4810
crossref_primary_10_1039_C6LC00526H
crossref_primary_10_3390_ijms21093233
crossref_primary_10_3390_biomedicines8120530
crossref_primary_10_3389_fonc_2018_00226
crossref_primary_10_3389_fonc_2018_00327
crossref_primary_10_1177_1758835920947342
crossref_primary_10_1186_s13148_018_0587_8
crossref_primary_10_3390_cancers13040624
crossref_primary_10_1186_s13046_020_01731_7
crossref_primary_10_3892_mco_2018_1578
crossref_primary_10_3389_fgene_2019_01245
crossref_primary_10_1016_j_bcp_2021_114409
crossref_primary_10_1111_cpr_12202
crossref_primary_10_1002_jcp_27221
crossref_primary_10_3390_cancers16183183
crossref_primary_10_4251_wjgo_v12_i9_942
crossref_primary_10_1016_j_humimm_2024_111221
crossref_primary_10_1016_j_biopha_2017_11_046
crossref_primary_10_3892_etm_2017_4021
crossref_primary_10_1016_j_semcancer_2022_05_012
crossref_primary_10_3390_biomedicines9121818
crossref_primary_10_1155_2016_5874127
crossref_primary_10_2174_1386207325666220909104803
crossref_primary_10_1177_1010428317697553
crossref_primary_10_2174_1389557523666230825144150
crossref_primary_10_3390_genes8030095
crossref_primary_10_1016_j_biopha_2017_08_084
crossref_primary_10_3390_molecules27196608
crossref_primary_10_3390_ijms19092791
crossref_primary_10_1007_s13105_024_01053_8
crossref_primary_10_3390_ijms21155353
Cites_doi 10.1038/nrc1893
10.1074/jbc.M109.031427
10.1128/MCB.01156-06
10.1016/j.molonc.2013.09.004
10.1371/journal.pone.0015797
10.1007/s12253-013-9695-0
10.1371/journal.pone.0062630
10.1038/cddis.2014.54
10.1186/1476-4598-5-24
10.1038/nrg2634
10.1177/1087057107306839
10.1016/S1097-2765(01)00341-0
10.1158/0008-5472.CAN-12-0103
10.1038/onc.2013.204
10.1007/s12272-009-1614-2
10.1158/0008-5472.CAN-09-4531
10.1371/journal.pone.0072400
10.1111/j.1349-7006.2009.01112.x
10.1038/sj.cdd.4401826
10.1371/journal.pone.0073345
10.1158/1078-0432.CCR-10-1664
10.1093/nar/gkt1275
10.1158/1078-0432.CCR-04-2223
10.1038/sj.embor.7400795
10.1200/JCO.2009.21.8172
10.1371/journal.pone.0034150
10.1093/jnci/djj306
10.1093/jnci/djm135
10.1158/0008-5472.CAN-12-3308
10.1002/ijc.20401
10.3390/molecules13081551
10.1016/j.canlet.2010.10.015
10.1038/nprot.2006.179
10.1097/00001813-200409000-00011
10.1158/0008-5472.CAN-09-1298
10.1073/pnas.90.8.3294
10.4062/biomolther.2010.18.4.375
10.3892/ol.2012.714
10.3892/ol.2012.775
10.3892/or.2012.2138
10.18632/oncotarget.2200
10.3892/or.2014.3337
ContentType Journal Article
Copyright The Pharmaceutical Society of Korea 2014
Copyright_xml – notice: The Pharmaceutical Society of Korea 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
ACYCR
DOI 10.1007/s12272-014-0528-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
AGRICOLA

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1976-3786
EndPage 248
ExternalDocumentID oai_kci_go_kr_ARTI_1136755
25502560
10_1007_s12272_014_0528_9
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-53
-56
-5G
-BR
-EM
-Y2
-~C
.86
.UV
.VR
06C
06D
0R~
0VY
1N0
2.D
203
23N
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2WC
2~H
30V
3SX
4.4
406
408
40D
40E
53G
5GY
5VS
67N
67Z
6J9
6NX
8TC
8UJ
95-
95.
95~
96X
9ZL
AAAVM
AABHQ
AACDK
AAHBH
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACREN
ACSNA
ACUDM
ACZOJ
ADHHG
ADHIR
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFGCZ
AFLOW
AFQWF
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BGNMA
C1A
CAG
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GRRUI
H13
HF~
HG6
HMJXF
HRMNR
HVGLF
HZ~
IJ-
IKXTQ
IWAJR
IXC
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
KPH
KVFHK
LLZTM
M4Y
MA-
MZR
N2Q
N9A
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OVD
P19
P2P
PF0
PT4
PT5
QOK
QOR
QOS
R89
R9I
RHV
RNI
RNS
ROL
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBL
SCLPG
SDE
SDH
SHX
SISQX
SJN
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TUC
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK6
WK8
YLTOR
Z45
Z7U
Z7V
Z7W
Z83
Z87
Z8O
Z8P
Z8Q
Z91
ZMTXR
ZOVNA
ZZE
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7S9
L.6
AABYN
AAFGU
AAKSU
AAPBV
AAYFA
ABFGW
ABKAS
ACBMV
ACBRV
ACBYP
ACIGE
ACIPQ
ACTTH
ACVWB
ACWMK
ACYCR
ADMDM
ADOXG
AEEQQ
AEFTE
AESTI
AEVTX
AFAFS
AFNRJ
AGGBP
AGKHE
AIMYW
AJDOV
AKQUC
UNUBA
Z7X
ID FETCH-LOGICAL-c444t-868bde098ee0a8f19b2c75c959f69965e00ba56d4b9586e188b63d7d12e4d4363
IEDL.DBID U2A
ISSN 0253-6269
1976-3786
IngestDate Tue Nov 21 21:33:46 EST 2023
Mon Jul 21 09:21:01 EDT 2025
Fri Sep 05 11:32:22 EDT 2025
Mon Jul 21 06:03:38 EDT 2025
Thu Apr 24 23:06:39 EDT 2025
Tue Jul 01 03:46:52 EDT 2025
Fri Feb 21 02:37:03 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords UBE2N
MicroRNA-96
XIAP
Drug resistance
5-FU
Apoptosis
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c444t-868bde098ee0a8f19b2c75c959f69965e00ba56d4b9586e188b63d7d12e4d4363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000010.2015.38.2.012
PMID 25502560
PQID 1652453059
PQPubID 23479
PageCount 10
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_1136755
proquest_miscellaneous_1733503948
proquest_miscellaneous_1652453059
pubmed_primary_25502560
crossref_citationtrail_10_1007_s12272_014_0528_9
crossref_primary_10_1007_s12272_014_0528_9
springer_journals_10_1007_s12272_014_0528_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-02-01
PublicationDateYYYYMMDD 2015-02-01
PublicationDate_xml – month: 02
  year: 2015
  text: 2015-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Heidelberg
PublicationPlace_xml – name: Heidelberg
– name: Korea (South)
PublicationTitle Archives of pharmacal research
PublicationTitleAbbrev Arch. Pharm. Res
PublicationTitleAlternate Arch Pharm Res
PublicationYear 2015
Publisher Pharmaceutical Society of Korea
대한약학회
Publisher_xml – name: Pharmaceutical Society of Korea
– name: 대한약학회
References Zhang, Yin, Xu, Chen (CR43) 2008; 13
Hamfjord, Stangeland, Hughes, Skrede, Tveit, Ikdahl, Kure (CR12) 2012; 7
Karasawa, Miura, Fujibuchi, Ishida, Kaneko, Kinouchi, Okabe, Ando, Murata, Sasaki, Takami, Yamamura, Shibata, Sasaki (CR14) 2009; 100
Arlt, Muerkoster, Schafer (CR1) 2013; 332
Chen, Xia, Xue, Ye (CR3) 2012; 5
Croce (CR5) 2009; 10
Laine, Topisirovic, Zhai, Reed, Borden, Ronai (CR18) 2006; 26
Manoochehri, Karbasi, Bandehpour, Kazemi (CR22) 2014; 20
Vichai, Kirtikara (CR35) 2006; 1
Xu, Qian, Deng, Cai, Tang, Wang, Zhang, Cai (CR39) 2012; 4
CR17
CR37
Lin, Dai, Xiong, Zhao, Chen, Yu, Li, Wang, Song (CR21) 2010; 5
Friedrich, Eder, Castaneda, Doss, Huber, Ebner, Kunz-Schughart (CR8) 2007; 12
Haflidadottir, Larne, Martin, Persson, Edsjo, Bjartell, Ceder (CR11) 2013; 8
Guttilla, White (CR10) 2009; 284
Mikhail, Eetezadi, Allen (CR24) 2013; 8
Broker, Kruyt, Giaccone (CR2) 2005; 11
Suzuki, Imai, Nakayama, Takahashi, Takio, Takahashi (CR31) 2001; 8
Wang, Huang, Calses, Kemp, Taniguchi (CR36) 2012; 72
Zhang, Pickard, Jenei, Bullock, Bruce, Mitter, Kelly, Paraskeva, Strefford, Primrose, Thomas, Packham, Mirnezami (CR42) 2013; 73
Schimmer, Dalili, Batey, Riedl (CR28) 2006; 13
Zhou, Wan, Spizzo, Ivan, Mathur, Hu, Ye, Lu, Fan, Xia, Calin, Ellis, Lu (CR44) 2014; 8
Mattie, Benz, Bowers, Sensinger, Wong, Scott, Fedele, Ginzinger, Getts, Haqq (CR23) 2006; 5
Schimmer, Estey, Borthakur, Carter, Schiller, Tallman, Altman, Karp, Kassis, Hedley, Brandwein, Xu, Mak, Lacasse, Jacob, Morris, Jolivet, Andreeff (CR29) 2009; 27
Kim, Choi, Kim, Kuh (CR16) 2009; 32
Tredan, Galmarini, Patel, Tannock (CR34) 2007; 99
Eckelman, Salvesen, Scott (CR6) 2006; 7
Schmidt, Kalipciyan, Dornstauder, Rizovski, Steger, Sedivy, Mueller, Mader (CR30) 2004; 112
Minchinton, Tannock (CR25) 2006; 6
Xu, He, Chang, Xu, Jiang, Sun, Lin (CR38) 2013; 29
Kashkar (CR15) 2010; 16
Tang, Zheng, Hu, Zeng, Li, Tucker, Monahan, Resnick, Liu, Ramratnam (CR33) 2014; 42
Yu, Lu, Liu, Meng, Ma, Zhao, Liu, Yu, Chen (CR41) 2010; 70
Lee, Nam, Park, Lee, Min Do, Kuh (CR19) 2014; 32
Ress, Stiegebauer, Winter, Schwarzenbacher, Kiesslich, Lax, Jahn, Deutsch, Bauernhofer, Ling, Samonigg, Gerger, Hoefler, Pichler (CR27) 2014
Hicks, Pruijn, Secomb, Hay, Hsu, Brown, Denny, Dewhirst, Wilson (CR13) 2006; 98
Feng, Yu, Pan, Li, Chen, Zhang, Wang, Yang, Xu, Zhang, Xu (CR7) 2014; 5
Li, Vandenboom, Kong, Wang, Ali, Philip, Sarkar (CR20) 2009; 69
Tanaka, Suzuki, Shibahara, Kunita, Isagawa, Yoshimi, Kurokawa, Miyazono, Aburatani, Ishikawa, Fukayama (CR32) 2014; 33
Guo, Liu, Zhang, Shang, Song (CR9) 2012; 4
Cheng, Fan, Xu, Zhang, Dou, Tang, Zhong, Rojas, Yu, Zhao, Vasudevan, Zhang, Nuchtern, Kim, Chen, Lu, Yang (CR4) 2014; 5
Park, Lee, Kang, Nishio, Saijo, Kuh (CR26) 2004; 15
Yeon, Da No, Lee, Nam, Oh, Lee, Kuh (CR40) 2013; 8
LE Broker (528_CR2) 2005; 11
H Karasawa (528_CR14) 2009; 100
Y Guo (528_CR9) 2012; 4
X Tang (528_CR33) 2014; 42
J Feng (528_CR7) 2014; 5
JK Park (528_CR26) 2004; 15
AD Schimmer (528_CR28) 2006; 13
RX Chen (528_CR3) 2012; 5
WM Schmidt (528_CR30) 2004; 112
Y Li (528_CR20) 2009; 69
J Cheng (528_CR4) 2014; 5
M Manoochehri (528_CR22) 2014; 20
AI Minchinton (528_CR25) 2006; 6
XM Xu (528_CR39) 2012; 4
A Arlt (528_CR1) 2013; 332
AS Mikhail (528_CR24) 2013; 8
IK Guttilla (528_CR10) 2009; 284
BS Haflidadottir (528_CR11) 2013; 8
H Kashkar (528_CR15) 2010; 16
MD Mattie (528_CR23) 2006; 5
M Tanaka (528_CR32) 2014; 33
Y Suzuki (528_CR31) 2001; 8
AD Schimmer (528_CR29) 2009; 27
SE Yeon (528_CR40) 2013; 8
528_CR17
D Xu (528_CR38) 2013; 29
528_CR37
SH Kim (528_CR16) 2009; 32
J Hamfjord (528_CR12) 2012; 7
Y Zhou (528_CR44) 2014; 8
KO Hicks (528_CR13) 2006; 98
S Yu (528_CR41) 2010; 70
J Friedrich (528_CR8) 2007; 12
Y Wang (528_CR36) 2012; 72
H Lin (528_CR21) 2010; 5
A Laine (528_CR18) 2006; 26
N Zhang (528_CR43) 2008; 13
AL Ress (528_CR27) 2014
BP Eckelman (528_CR6) 2006; 7
O Tredan (528_CR34) 2007; 99
V Vichai (528_CR35) 2006; 1
L Zhang (528_CR42) 2013; 73
CM Croce (528_CR5) 2009; 10
SH Lee (528_CR19) 2014; 32
References_xml – volume: 6
  start-page: 583
  year: 2006
  end-page: 592
  ident: CR25
  article-title: Drug penetration in solid tumours
  publication-title: Nature Reviews Cancer
  doi: 10.1038/nrc1893
– volume: 284
  start-page: 23204
  year: 2009
  end-page: 23216
  ident: CR10
  article-title: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells
  publication-title: Journal of Biological Chemistry
  doi: 10.1074/jbc.M109.031427
– volume: 26
  start-page: 8901
  year: 2006
  end-page: 8913
  ident: CR18
  article-title: Regulation of p53 localization and activity by Ubc13
  publication-title: Molecular and Cellular Biology
  doi: 10.1128/MCB.01156-06
– volume: 5
  start-page: 5832
  year: 2014
  end-page: 5844
  ident: CR7
  article-title: HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96
  publication-title: Oncotarget
– volume: 8
  start-page: 83
  year: 2014
  end-page: 92
  ident: CR44
  article-title: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase
  publication-title: Molecular Oncology
  doi: 10.1016/j.molonc.2013.09.004
– volume: 32
  start-page: 1427
  year: 2014
  end-page: 1434
  ident: CR19
  article-title: Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model
  publication-title: Oncology Reports
– volume: 5
  start-page: e15797
  year: 2010
  ident: CR21
  article-title: Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0015797
– volume: 29
  start-page: 653
  year: 2013
  end-page: 661
  ident: CR38
  article-title: Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells
  publication-title: Oncology Reports
– volume: 20
  start-page: 301
  year: 2014
  end-page: 307
  ident: CR22
  article-title: Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer
  publication-title: Pathology & Oncology Research
  doi: 10.1007/s12253-013-9695-0
– volume: 8
  start-page: e62630
  year: 2013
  ident: CR24
  article-title: Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: A comparison of docetaxel-loaded block copolymer micelles and Taxotere(R)
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0062630
– ident: CR37
– volume: 5
  start-page: 800
  year: 2012
  end-page: 804
  ident: CR3
  article-title: Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells
  publication-title: Molecular Medicine Reports
– volume: 5
  start-page: e1079
  year: 2014
  ident: CR4
  article-title: A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways
  publication-title: Cell Death and Disease
  doi: 10.1038/cddis.2014.54
– volume: 5
  start-page: 24
  year: 2006
  ident: CR23
  article-title: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies
  publication-title: Molecular Cancer
  doi: 10.1186/1476-4598-5-24
– volume: 10
  start-page: 704
  year: 2009
  end-page: 714
  ident: CR5
  article-title: Causes and consequences of microRNA dysregulation in cancer
  publication-title: Nature Reviews Genetics
  doi: 10.1038/nrg2634
– volume: 4
  start-page: 339
  year: 2012
  end-page: 345
  ident: CR39
  article-title: Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer
  publication-title: Oncology Letters
– volume: 12
  start-page: 925
  year: 2007
  end-page: 937
  ident: CR8
  article-title: A reliable tool to determine cell viability in complex 3-d culture: The acid phosphatase assay
  publication-title: Journal of Biomolecular Screening
  doi: 10.1177/1087057107306839
– volume: 8
  start-page: 613
  year: 2001
  end-page: 621
  ident: CR31
  article-title: A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death
  publication-title: Molecular Cell
  doi: 10.1016/S1097-2765(01)00341-0
– volume: 72
  start-page: 4037
  year: 2012
  end-page: 4046
  ident: CR36
  article-title: MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-12-0103
– volume: 33
  start-page: 2454
  year: 2014
  end-page: 2463
  ident: CR32
  article-title: EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis
  publication-title: Oncogene
  doi: 10.1038/onc.2013.204
– volume: 32
  start-page: 915
  year: 2009
  end-page: 922
  ident: CR16
  article-title: Anti-tumor activity of noble indirubin derivatives in human solid tumor models in vitro
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-009-1614-2
– volume: 70
  start-page: 6015
  year: 2010
  end-page: 6025
  ident: CR41
  article-title: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-09-4531
– volume: 8
  start-page: e72400
  year: 2013
  ident: CR11
  article-title: Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0072400
– volume: 100
  start-page: 903
  year: 2009
  end-page: 913
  ident: CR14
  article-title: Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells
  publication-title: Cancer Science
  doi: 10.1111/j.1349-7006.2009.01112.x
– volume: 13
  start-page: 179
  year: 2006
  end-page: 188
  ident: CR28
  article-title: Targeting XIAP for the treatment of malignancy
  publication-title: Cell Death and Differentiation
  doi: 10.1038/sj.cdd.4401826
– volume: 8
  start-page: e73345
  year: 2013
  ident: CR40
  article-title: Application of concave microwells to pancreatic tumor spheroids enabling anticancer drug evaluation in a clinically relevant drug resistance model
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073345
– volume: 16
  start-page: 4496
  year: 2010
  end-page: 4502
  ident: CR15
  article-title: X-linked inhibitor of apoptosis: A chemoresistance factor or a hollow promise
  publication-title: Clinical Cancer Research
  doi: 10.1158/1078-0432.CCR-10-1664
– volume: 42
  start-page: 2988
  year: 2014
  end-page: 2998
  ident: CR33
  article-title: Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the beta-Catenin/TCF/LEF-1 pathway in gastric cancer cells
  publication-title: Nucleic Acids Research
  doi: 10.1093/nar/gkt1275
– volume: 11
  start-page: 3155
  year: 2005
  end-page: 3162
  ident: CR2
  article-title: Cell death independent of caspase: A review
  publication-title: Clinical Cancer Research
  doi: 10.1158/1078-0432.CCR-04-2223
– volume: 7
  start-page: 988
  year: 2006
  end-page: 994
  ident: CR6
  article-title: Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family
  publication-title: EMBO Reports
  doi: 10.1038/sj.embor.7400795
– volume: 4
  start-page: 561
  year: 2012
  end-page: 565
  ident: CR9
  article-title: miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer
  publication-title: Oncology Letters
– ident: CR17
– volume: 27
  start-page: 4741
  year: 2009
  end-page: 4746
  ident: CR29
  article-title: Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia
  publication-title: Journal of Clinical Oncology
  doi: 10.1200/JCO.2009.21.8172
– year: 2014
  ident: CR27
  article-title: MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients
  publication-title: Molecular Carcinogenesis
– volume: 7
  start-page: e34150
  year: 2012
  ident: CR12
  article-title: Differential expression of miRNAs in colorectal cancer: Comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0034150
– volume: 98
  start-page: 1118
  year: 2006
  end-page: 1128
  ident: CR13
  article-title: Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs
  publication-title: Journal of the National Cancer Institute
  doi: 10.1093/jnci/djj306
– volume: 99
  start-page: 1441
  year: 2007
  end-page: 1454
  ident: CR34
  article-title: Drug resistance and the solid tumor microenvironment
  publication-title: Journal of the National Cancer Institute
  doi: 10.1093/jnci/djm135
– volume: 73
  start-page: 6435
  year: 2013
  end-page: 6447
  ident: CR42
  article-title: miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-12-3308
– volume: 112
  start-page: 200
  year: 2004
  end-page: 212
  ident: CR30
  article-title: Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling
  publication-title: International Journal of Cancer
  doi: 10.1002/ijc.20401
– volume: 13
  start-page: 1551
  year: 2008
  end-page: 1569
  ident: CR43
  article-title: 5-Fluorouracil: Mechanisms of resistance and reversal strategies
  publication-title: Molecules
  doi: 10.3390/molecules13081551
– volume: 332
  start-page: 346
  year: 2013
  end-page: 358
  ident: CR1
  article-title: Targeting apoptosis pathways in pancreatic cancer
  publication-title: Cancer Letters
  doi: 10.1016/j.canlet.2010.10.015
– volume: 1
  start-page: 1112
  year: 2006
  end-page: 1116
  ident: CR35
  article-title: Sulforhodamine B colorimetric assay for cytotoxicity screening
  publication-title: Nature Protocols
  doi: 10.1038/nprot.2006.179
– volume: 15
  start-page: 809
  year: 2004
  end-page: 818
  ident: CR26
  article-title: Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/00001813-200409000-00011
– volume: 69
  start-page: 6704
  year: 2009
  end-page: 6712
  ident: CR20
  article-title: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-09-1298
– volume: 7
  start-page: 988
  year: 2006
  ident: 528_CR6
  publication-title: EMBO Reports
  doi: 10.1038/sj.embor.7400795
– volume: 99
  start-page: 1441
  year: 2007
  ident: 528_CR34
  publication-title: Journal of the National Cancer Institute
  doi: 10.1093/jnci/djm135
– ident: 528_CR17
  doi: 10.1073/pnas.90.8.3294
– volume: 5
  start-page: 800
  year: 2012
  ident: 528_CR3
  publication-title: Molecular Medicine Reports
– ident: 528_CR37
  doi: 10.4062/biomolther.2010.18.4.375
– volume: 10
  start-page: 704
  year: 2009
  ident: 528_CR5
  publication-title: Nature Reviews Genetics
  doi: 10.1038/nrg2634
– volume: 98
  start-page: 1118
  year: 2006
  ident: 528_CR13
  publication-title: Journal of the National Cancer Institute
  doi: 10.1093/jnci/djj306
– volume: 12
  start-page: 925
  year: 2007
  ident: 528_CR8
  publication-title: Journal of Biomolecular Screening
  doi: 10.1177/1087057107306839
– volume: 5
  start-page: e1079
  year: 2014
  ident: 528_CR4
  publication-title: Cell Death and Disease
  doi: 10.1038/cddis.2014.54
– volume: 69
  start-page: 6704
  year: 2009
  ident: 528_CR20
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-09-1298
– volume: 8
  start-page: 613
  year: 2001
  ident: 528_CR31
  publication-title: Molecular Cell
  doi: 10.1016/S1097-2765(01)00341-0
– volume: 5
  start-page: e15797
  year: 2010
  ident: 528_CR21
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0015797
– volume: 32
  start-page: 915
  year: 2009
  ident: 528_CR16
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-009-1614-2
– year: 2014
  ident: 528_CR27
  publication-title: Molecular Carcinogenesis
– volume: 332
  start-page: 346
  year: 2013
  ident: 528_CR1
  publication-title: Cancer Letters
  doi: 10.1016/j.canlet.2010.10.015
– volume: 4
  start-page: 339
  year: 2012
  ident: 528_CR39
  publication-title: Oncology Letters
  doi: 10.3892/ol.2012.714
– volume: 4
  start-page: 561
  year: 2012
  ident: 528_CR9
  publication-title: Oncology Letters
  doi: 10.3892/ol.2012.775
– volume: 8
  start-page: e73345
  year: 2013
  ident: 528_CR40
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073345
– volume: 8
  start-page: e62630
  year: 2013
  ident: 528_CR24
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0062630
– volume: 284
  start-page: 23204
  year: 2009
  ident: 528_CR10
  publication-title: Journal of Biological Chemistry
  doi: 10.1074/jbc.M109.031427
– volume: 29
  start-page: 653
  year: 2013
  ident: 528_CR38
  publication-title: Oncology Reports
  doi: 10.3892/or.2012.2138
– volume: 6
  start-page: 583
  year: 2006
  ident: 528_CR25
  publication-title: Nature Reviews Cancer
  doi: 10.1038/nrc1893
– volume: 72
  start-page: 4037
  year: 2012
  ident: 528_CR36
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-12-0103
– volume: 5
  start-page: 5832
  year: 2014
  ident: 528_CR7
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2200
– volume: 8
  start-page: e72400
  year: 2013
  ident: 528_CR11
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0072400
– volume: 16
  start-page: 4496
  year: 2010
  ident: 528_CR15
  publication-title: Clinical Cancer Research
  doi: 10.1158/1078-0432.CCR-10-1664
– volume: 27
  start-page: 4741
  year: 2009
  ident: 528_CR29
  publication-title: Journal of Clinical Oncology
  doi: 10.1200/JCO.2009.21.8172
– volume: 7
  start-page: e34150
  year: 2012
  ident: 528_CR12
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0034150
– volume: 11
  start-page: 3155
  year: 2005
  ident: 528_CR2
  publication-title: Clinical Cancer Research
  doi: 10.1158/1078-0432.CCR-04-2223
– volume: 26
  start-page: 8901
  year: 2006
  ident: 528_CR18
  publication-title: Molecular and Cellular Biology
  doi: 10.1128/MCB.01156-06
– volume: 42
  start-page: 2988
  year: 2014
  ident: 528_CR33
  publication-title: Nucleic Acids Research
  doi: 10.1093/nar/gkt1275
– volume: 1
  start-page: 1112
  year: 2006
  ident: 528_CR35
  publication-title: Nature Protocols
  doi: 10.1038/nprot.2006.179
– volume: 33
  start-page: 2454
  year: 2014
  ident: 528_CR32
  publication-title: Oncogene
  doi: 10.1038/onc.2013.204
– volume: 15
  start-page: 809
  year: 2004
  ident: 528_CR26
  publication-title: Anti-Cancer Drugs
  doi: 10.1097/00001813-200409000-00011
– volume: 13
  start-page: 1551
  year: 2008
  ident: 528_CR43
  publication-title: Molecules
  doi: 10.3390/molecules13081551
– volume: 8
  start-page: 83
  year: 2014
  ident: 528_CR44
  publication-title: Molecular Oncology
  doi: 10.1016/j.molonc.2013.09.004
– volume: 20
  start-page: 301
  year: 2014
  ident: 528_CR22
  publication-title: Pathology & Oncology Research
  doi: 10.1007/s12253-013-9695-0
– volume: 32
  start-page: 1427
  year: 2014
  ident: 528_CR19
  publication-title: Oncology Reports
  doi: 10.3892/or.2014.3337
– volume: 13
  start-page: 179
  year: 2006
  ident: 528_CR28
  publication-title: Cell Death and Differentiation
  doi: 10.1038/sj.cdd.4401826
– volume: 112
  start-page: 200
  year: 2004
  ident: 528_CR30
  publication-title: International Journal of Cancer
  doi: 10.1002/ijc.20401
– volume: 70
  start-page: 6015
  year: 2010
  ident: 528_CR41
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-09-4531
– volume: 73
  start-page: 6435
  year: 2013
  ident: 528_CR42
  publication-title: Cancer Research
  doi: 10.1158/0008-5472.CAN-12-3308
– volume: 100
  start-page: 903
  year: 2009
  ident: 528_CR14
  publication-title: Cancer Science
  doi: 10.1111/j.1349-7006.2009.01112.x
– volume: 5
  start-page: 24
  year: 2006
  ident: 528_CR23
  publication-title: Molecular Cancer
  doi: 10.1186/1476-4598-5-24
SSID ssj0036555
Score 2.2821853
Snippet 5-FU is an anticancer drug that is widely used to treat cancers, including colorectal cancer (CRC); however, chemoresistance to 5-FU remains an important...
5-FU is an anticancer drug that is widely used totreat cancers, including colorectal cancer (CRC); however,chemoresistance to 5-FU remains an important problem...
SourceID nrf
proquest
pubmed
crossref
springer
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 239
SubjectTerms Antimetabolites, Antineoplastic - pharmacology
antineoplastic agents
apoptosis
Apoptosis - drug effects
Apoptosis - genetics
Cell Culture Techniques
colorectal neoplasms
drug resistance
Drug Resistance, Neoplasm - genetics
Fluorouracil - pharmacology
gene expression regulation
gene overexpression
genes
growth retardation
HCT116 Cells
HT29 Cells
Humans
luciferase
Medicine
microRNA
MicroRNAs - antagonists & inhibitors
MicroRNAs - genetics
neoplasm cells
Pharmacology/Toxicology
Pharmacy
Research Article
Spheroids, Cellular - drug effects
Spheroids, Cellular - pathology
Transfection
Ubiquitin-Conjugating Enzymes - genetics
Up-Regulation
X-Linked Inhibitor of Apoptosis Protein - genetics
약학
Title Indirect modulation of sensitivity to 5-fluorouracil by microRNA-96 in human colorectal cancer cells
URI https://link.springer.com/article/10.1007/s12272-014-0528-9
https://www.ncbi.nlm.nih.gov/pubmed/25502560
https://www.proquest.com/docview/1652453059
https://www.proquest.com/docview/1733503948
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001962657
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Archives of Pharmacal Research, 2015, 38(2), , pp.239-248
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZNAqWX0qav7SOopeTQRiDrZem4lKRJS0IoWUhPwno4LNnYxd497L_vyI8spWmgJ1_ksdC8vvGMZhD6CFJkGHUlKQodiAheEhdVIMzxaJzRwXc_c07P1PFMfLuUl8M97nasdh9Tkp2l3lx2YyxPZQSCUMlAS7fQjoTQPWnjjE1H88uV7Eadgi_nBNC6GVOZd5H4wxltVU15F878K0fauZ6jJ-jxgBnxtGfyU_QgVrvo4emQFd9F--d9_-n1Ab7YXKdqD_A-Pt90pl4_Q-Gk6l0YvqnDMLcL1yVuUxV7P0YCL2ssSblY1Q18tvDzBXZrfJPK9n6cTYlReF7hbrAfTlQTMdiaT7LT4JQFaJ-j2dHhxZdjMoxZIF4IsSRaaRciNTpGWugyM475XHojTakgGpKRUldIFYQzUquYae0UD3nIWBRBcMVfoO2qruIrhHMhIvMsZLT0onRcSwcIT3OXe6DkzATR8bytH3qQp1EYC7vpnpxYZIFFNrHIwiufbl_51TfguG_xB2CivfZzm9pmp-dVba8bC8HBiU3ja3IpJ-j9yGMLupSOpqhivWptpiQTEiyguWdNzrmk3Ag9QS97AbndF4RnHYScoM-jxNjBJLT_3vTr_1r9Bj0CzCb7wvG3aHvZrOI7wEVLt4d2pl9_fj_c6_ThN3WYA64
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9NAEF7RVAJeOMrRcC4I9YF2K3sv7z5GqCWhTVShVCpPK-9hFCW1q9h5CL-eXR-NgFKpT35Zj8fj2Tk8s98A8MlrkcSRzlCaCouoNQxpxy3CmjippbCm_pkznvDhOf12wS7ac9xl1-3elSRrS7057IZxEtoIKIoY9rt0C2xTn4JHPbA9-Prj5KgzwISzetip9-YE-XhddsXMm4j84Y628mV2U6T5T5W0dj7Hj8G0Y7vpOZkfrip9aH79heh4x_d6Ah61wSgcNNrzFNxz-Q64P27L7Ttg76wBtl4fwOnmnFZ5APfg2Qbyev0M2FHe-EZ4Wdh2IBgsMliG9vhmPgWsCshQtlgVS__Y1MwWUK_hZegH_D4ZIMnhLIf1xEAYqAZinjUTlHIJQ3mhfA7Oj4-mX4aond-ADKW0QoILbV0khXNRKrJYamwSZiSTGfdpFnNRpFPGLdWSCe5iITQnNrExdtRSwskL0MuL3O0CmFDqsME2jjJDM00E0z50FEQnxlPSsg-i7jMq04KbhxkbC7WBZQ5iVl7MKohZ-Vs-X99y1SB73Lb4o9cNNTczFfC4w_VnoeZL5bOOkQpzcRLG-uBDpzrKb9IgmjR3xapUMWeYMm9a5S1rEkJYRCQVffCy0btrvnzeV8emfbDf6ZBqbU35f6Zf3Wn1e_BgOB2fqtPR5OQ1eOgDQ9Z0p78BvWq5cm998FXpd-1m-w2d7CHP
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZNCqGXkqaPbJ9qKTm0EbH1snRc2i7ZtlmWkoXchPUqSzZ2sL2H_feR_MhSmgZ68kUeC81oZuQZfR8AH4MVSZxoj_JcWEStYUg7bhHWxEkthTXtz5yzGT9d0O8X7KLnOa2HbvehJNndaYgoTUVzcm39yfbiG8ZZbCmgKGE47Ngd8DB44zQa-gKPB1dMOGtpT0NcJyhk7nIoa94l4o_AtFNU_q6c8696aRuGJvvgcZ8_wnGn8CfggSsOwN5ZXyE_AEfzDot6cwzPt1er6mN4BOdblOrNU2CnRRfO4FVpew4vWHpYx472jlICNiVkyK_WZRU-m5vlCuoNvIotfL9mYyQ5XBawJfmDUWoUFqZmoh1VMFYE6mdgMfl2_uUU9ZQLyFBKGyS40NYlUjiX5MKnUmOTMSOZ9DycjJhLEp0zbqmWTHCXCqE5sZlNsaOWEk6eg92iLNwhgBmlDhts08Qb6jURTIdsTxCdmSBJyxFIhvVWpscjj7QYK7VFUo4qUkFFKqpIhVc-3b5y3YFx3Df4Q1CiujRLFSG04_N3qS4rFQ4KUxWpbDLGRuD9oGMV9lVcmrxw5bpWKWeYsuAN5T1jMkJYQiQVI_CiM5DbeYWjWptOjsDnwWJU7x7qf0_65X-Nfgf25l8n6ud09uMVeBRSOdb1k78Gu021dm9CutTot-2WuAGyXglJ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Indirect+modulation+of+sensitivity+to+5-fluorouracil+by+microRNA-96+in+human+colorectal+cancer+cells&rft.jtitle=Archives+of+pharmacal+research&rft.au=Kim%2C+Sun-Ah&rft.au=Kim%2C+Injung&rft.au=Yoon%2C+Sungjoo+Kim&rft.au=Lee%2C+Eun+Kyung&rft.date=2015-02-01&rft.issn=1976-3786&rft.eissn=1976-3786&rft.volume=38&rft.issue=2&rft.spage=239&rft_id=info:doi/10.1007%2Fs12272-014-0528-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0253-6269&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0253-6269&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0253-6269&client=summon